1. Home
  2. VLY vs INAB Comparison

VLY vs INAB Comparison

Compare VLY & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

HOLD

Current Price

$12.92

Market Cap

6.9B

Sector

Finance

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.46

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLY
INAB
Founded
1927
2016
Country
United States
United States
Employees
3675
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
14.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VLY
INAB
Price
$12.92
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
1
Target Price
$14.17
$6.00
AVG Volume (30 Days)
7.0M
73.5K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
3.49%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.52
N/A
Revenue Next Year
$8.60
N/A
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.64
$0.12
52 Week High
$13.87
$4.20

Technical Indicators

Market Signals
Indicator
VLY
INAB
Relative Strength Index (RSI) 63.31 43.78
Support Level $11.61 $1.48
Resistance Level $13.87 $2.14
Average True Range (ATR) 0.30 0.16
MACD 0.12 -0.01
Stochastic Oscillator 86.09 20.59

Price Performance

Historical Comparison
VLY
INAB

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: